Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
Status:
Recruiting
Trial end date:
2022-10-20
Target enrollment:
Participant gender:
Summary
The analysis of our own clinical data suggests that majority of the hematologic responses
observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine
dependence.
The aim of the current study is to improve the rate and the quality of hematologic response
as well as to prevent delayed complications such as relapse and clonal progression by means
of adding eltrombopag to standard immunosuppressive therapy
Phase:
Phase 3
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology